Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Koski, Anniina ^a   Karli, Eerika ^a   Kipar, Anja ^b,c   Escutenaire, Sophie ^a   Kanerva, Anna ^a,d   Hemminki, Akseli ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9; CYTOKINE; HEPARAN SULFATE; WARFARIN;

ADENOVIRUS; ADENOVIRUS 3; ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BIOACCUMULATION; CHIMERA; CONTROLLED STUDY; CYTOKINE RESPONSE; EMBRYO; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KUPFFER CELL; LIVER CELL; MOUSE; NONHUMAN; TRANSGENE; TUMOR XENOGRAFT; VIRAL TROPISM; VIRUS ATTACHMENT; VIRUS GENE; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; BINDING SITES; BLOOD COAGULATION FACTORS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HEPARITIN SULFATE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MICE; MICE, NUDE; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; REASSORTANT VIRUSES; TRANSDUCTION, GENETIC; TRANSGENES; VIRAL TROPISM; WARFARIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 84876021714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060032     Document Type: Article

References (64)

1. Fukuhara H, Homma Y, Todo T, (2009) Oncolytic virus therapy for prostate cancer. Int J Urol 17: 20-30.
2. Liang M (2011) Clinical Development of Oncolytic viruses in China. Curr Pharm Biotechnol.
3. Toth K, Wold WS, (2010) Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2: 1844-1866.
4. Nemunaitis J, Senzer N, Sarmiento S, Zhang YA, Arzaga R, et al. (2007) A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther 14: 885-893.
5. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, et al. (2006) A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
6. Vrancken Peeters MJ, Perkins AL, Kay MA, (1996) Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 20: 278-285.
7. Fechner H, Haack A, Wang H, Wang X, Eizema K, et al. (1999) Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 6: 1520-1535.
8. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, et al. (2002) Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 5: 695-704.
9. Hofherr SE, Adams KE, Chen CY, May S, Weaver EA, et al. (2011) Real-time dynamic imaging of virus distribution in vivo. PLoS One 6: e17076.
10. Nunes FA, Furth EE, Wilson JM, Raper SE, (1999) Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. Hum Gene Ther 10: 2515-2526.
11. Reid T, Warren R, Kirn D, (2002) Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9: 979-986.
12. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, et al. (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
13. Muruve DA, Barnes MJ, Stillman IE, Libermann TA, (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10: 965-976.
14. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, et al. (2001) Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 3: 708-722.
15. Tao N, Gao GP, Parr M, Johnston J, Baradet T, et al. (2001) Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3: 28-35.
16. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, et al. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158.
17. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A, (2005) Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 79: 7478-7491.
18. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G, (2000) Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268: 382-390.
19. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, et al. (2001) Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 75: 8772-8780.
20. Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, et al. (2003) Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 14: 1595-1604.
21. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, et al. (2003) Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 14: 777-787.
22. Nicol CG, Graham D, Miller WH, White SJ, Smith TA, et al. (2004) Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther 10: 344-354.
23. Kritz AB, Nicol CG, Dishart KL, Nelson R, Holbeck S, et al. (2007) Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Mol Ther 15: 741-749.
24. Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, et al. (2009) Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther 20: 1214-1221.
25. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, et al. (2006) Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther 17: 264-279.
26. Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, et al. (2006) Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol 87: 2487-2495.
27. Wu E, Pache L, Von Seggern DJ, Mullen TM, Mikyas Y, et al. (2003) Flexibility of the adenovirus fiber is required for efficient receptor interaction. J Virol 77: 7225-7235.
28. Shayakhmetov DM, Lieber A, (2000) Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol 74: 10274-10286.
29. Law LK, Davidson BL, (2005) What does it take to bind CAR? Mol Ther 12: 599-609.
30. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT, (1996) Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70: 6839-6846.
31. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, et al. (2002) Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8: 275-280.
32. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, et al. (2003) Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8: 449-458.
33. Volk AL, Rivera AA, Kanerva A, Bauerschmitz G, Dmitriev I, et al. (2003) Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther 2: 511-515.
34. Kangasniemi L, Kiviluoto T, Kanerva A, Raki M, Ranki T, et al. (2006) Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res 12: 3137-3144.
35. Guse K, Ranki T, Ala-Opas M, Bono P, Sarkioja M, et al. (2007) Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 6: 2728-2736.
36. Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, et al. (2007) Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther 6: 742-751.
37. Ranki T, Sarkioja M, Hakkarainen T, von Smitten K, Kanerva A, et al. (2007) Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer 121: 165-174.
38. Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, et al. (2007) Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 9: 151-160.
39. Short JJ, Vasu C, Holterman MJ, Curiel DT, Pereboev A, (2006) Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res 122: 144-153.
40. Wang H, Li ZY, Liu Y, Persson J, Beyer I, et al. (2011) Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 17: 96-104.
41. Tuve S, Wang H, Jacobs JD, Yumul RC, Smith DF, et al. (2008) Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog 4: e1000189.
42. Trinh HV, Lesage G, Chennamparampil V, Vollenweider B, Burckhardt CJ, et al. (2012) Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. J Virol 86: 1623-1637.
43. Tuve S, Wang H, Ware C, Liu Y, Gaggar A, et al. (2006) A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 80: 12109-12120.
44. Wang H, Beyer I, Persson J, Song H, Li Z, et al. (2012) A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol 86: 6286-6302.
45. Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, et al. (2012) Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 72: 2327-2338.
46. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108: 2554-2561.
47. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409.
48. Waddington SN, Parker AL, Havenga M, Nicklin SA, Buckley SM, et al. (2007) Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol 81: 9568-9571.
49. Shashkova EV, Doronin K, Senac JS, Barry MA, (2008) Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res 68: 5896-5904.
50. Koski A, Rajecki M, Guse K, Kanerva A, Ristimaki A, et al. (2009) Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J Gene Med 11: 966-977.
51. Goodison S, Viars C, Urquidi V, (2005) Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements. Cancer Genet Cytogenet 156: 37-48.
52. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC, (1993) Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898.
53. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT, (2001) Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 75: 4176-4183.
54. Uil TG, Seki T, Dmitriev I, Kashentseva E, Douglas JT, et al. (2003) Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. Cancer Gene Ther 10: 121-124.
55. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, Bartolome M, Arroyo R, (2007) Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. Eur J Neurol 14: 233-236.
56. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, et al. (2001) Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res 61: 6377-6381.
57. Khare R, Chen CY, Weaver EA, Barry MA, (2011) Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11: 241-258.
58. Di Paolo NC, Kalyuzhniy O, Shayakhmetov DM, (2007) Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo. J Virol 81: 12249-12259.
59. Corjon S, Gonzalez G, Henning P, Grichine A, Lindholm L, et al. (2011) Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction. PLoS One 6: e18205.
60. Parker AL, McVey JH, Doctor JH, Lopez-Franco O, Waddington SN, et al. (2007) Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J Virol. 81: 3627-3631.
61. Gimenez-Alejandre M, Cascallo M, Bayo-Puxan N, Alemany R, (2008) Coagulation factors determine tumor transduction in vivo. Hum Gene Ther 19: 1415-1419.
62. Alba R, Bradshaw AC, Mestre-Frances N, Verdier JM, Henaff D, et al. (2011) Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Ther 19: 109-113.
63. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114: 965-971.
64. Alba R, Bradshaw AC, Coughlan L, Denby L, McDonald RA, et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116: 2656-2664.